 Odonate Therapeutics NASDAQ:ODT was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research report issued to clients and investors on Saturday, Zacks.com reports. The brokerage currently has a 31.00 target price on the stock. Zacks Investment Researchs target price would suggest a potential upside of 9.93 from the ... 